| Business Summary | | Caraco
Pharmaceutical
Laboratories,
Ltd.
is
engaged
in
the
business
of
developing,
manufacturing
and
marketing
generic
drugs
for
the
ethical
(prescription)
and
non-prescription
or
over-the-counter
markets.
Caraco's
product
portfolio
includes
13
products
in
20
strengths
in
34
package
sizes.
Of
these
13
products,
four
have
been
temporarily
discontinued
until
the
Company
successfully
completes
the
next
Food
and
Drug
Administration
(FDA)
inspection.
The
Company
has
submitted
nine
Abbreviated
New
Drug
Applications
(ANDAs)
to
the
FDA
for
approval.
During
2000,
the
dedicated
development
laboratory
of
Sun
Pharmaceutical
Industries
Ltd.
in
Bombay
was
actively
working
on
multiple
ANDA
submissions
in
connection
with
its
agreement
with
the
Company.
Sun
Pharma
has
facilitated
the
transfer
of
technology
to
Caraco
with
respect
to
10
products.
Including
the
transfer
of
technology
by
Sun
Pharma,
the
Company
has
21
products
in
various
stages
of
active
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | CARA
engages
in
the
business
of
developing,
manufacturing
and
marketing
generic
drugs
for
ethical
and
over-the-counter
markets.
For
the
three
months
ended
3/31/01,
net
sales
increased
21%
to
$943
thousand.
Net
loss
increased
1%
to
$1.7
million.
Revenues
reflect
increased
production
and
new
drug
development.
Net
loss
reflects
increased
S/G/A
expenses
due
to
costs
incurred
for
FDA
compliance
and
the
retention
of
an
FDA
consulting
firm. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
925;
after
tax
earnings
were
-1,953. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Dilip Shanghvi, 45 Chairman | -- | Narendra Borkar, 60 CEO | $130K | Jitendra Doshi, 50 Sr.
VP, Commercial | -- | Robert Kurkiewicz, 50 Sr.
VP, Technical | 125K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|